These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23229814)

  • 1. Omalizumab: NICE to USE you, to LOSE you NICE.
    Bush A; Pavord ID
    Thorax; 2013 Jan; 68(1):7-8. PubMed ID: 23229814
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab under 12 years old: real-life practice.
    Pite H; Gaspar Â; Paiva M; Leiria-Pinto P
    Allergol Immunopathol (Madr); 2013; 41(2):133-6. PubMed ID: 22560014
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab in patients with severe asthma: the XCLUSIVE study.
    Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
    Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE guidance on omalizumab for severe asthma.
    Diaz RA; Charles Z; George E; Adler AI
    Lancet Respir Med; 2013 May; 1(3):189-90. PubMed ID: 24429120
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
    J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
    Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
    Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R; Marco AG; Cohen D; Canonica GW
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.
    Hendeles L; Khan YR; Shuster JJ; Chesrown SE; Abu-Hasan M
    Ann Allergy Asthma Immunol; 2015 Jan; 114(1):58-62.e2. PubMed ID: 25528738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of omalizumab dosage in patients with severe persistent allergic asthma using recoveryELISA.
    Steiß JO; Becher G
    BioDrugs; 2014 Oct; 28(5):445-50. PubMed ID: 24898594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
    Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
    [No Abstract]   [Full Text] [Related]  

  • 20. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.